HK1219273A1 - 磷酸二酯酶 型的新型抑制劑化合物 - Google Patents
磷酸二酯酶 型的新型抑制劑化合物Info
- Publication number
- HK1219273A1 HK1219273A1 HK16107260.0A HK16107260A HK1219273A1 HK 1219273 A1 HK1219273 A1 HK 1219273A1 HK 16107260 A HK16107260 A HK 16107260A HK 1219273 A1 HK1219273 A1 HK 1219273A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibitor compounds
- phosphodiesterase type
- novel inhibitor
- novel
- phosphodiesterase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779141P | 2013-03-13 | 2013-03-13 | |
| PCT/EP2014/054810 WO2014140086A1 (en) | 2013-03-13 | 2014-03-12 | Novel inhibitor compounds of phosphodiesterase type 10a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1219273A1 true HK1219273A1 (zh) | 2017-03-31 |
Family
ID=50241454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16107260.0A HK1219273A1 (zh) | 2013-03-13 | 2016-06-22 | 磷酸二酯酶 型的新型抑制劑化合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9200005B2 (zh) |
| EP (1) | EP2970328B1 (zh) |
| JP (1) | JP2016510786A (zh) |
| KR (1) | KR20150127724A (zh) |
| CN (1) | CN105358561A (zh) |
| AR (1) | AR095267A1 (zh) |
| AU (1) | AU2014230825A1 (zh) |
| BR (1) | BR112015022094A2 (zh) |
| CA (1) | CA2902654A1 (zh) |
| CL (1) | CL2015002545A1 (zh) |
| CR (1) | CR20150496A (zh) |
| DO (1) | DOP2015000214A (zh) |
| HK (1) | HK1219273A1 (zh) |
| IL (1) | IL240593A0 (zh) |
| MX (1) | MX2015012389A (zh) |
| PE (1) | PE20160040A1 (zh) |
| PH (1) | PH12015501962A1 (zh) |
| RU (1) | RU2015143536A (zh) |
| SG (1) | SG11201507380PA (zh) |
| TW (1) | TW201441230A (zh) |
| UY (1) | UY35393A (zh) |
| WO (1) | WO2014140086A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015011445A (es) | 2013-03-15 | 2016-04-20 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina. |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| JP6767969B2 (ja) * | 2014-09-05 | 2020-10-14 | ジェネンテック， インコーポレイテッド | がんの処置における使用のためのｐｃａｆおよびｇｃｎ５阻害剤としての式（ｉ）のフタラジン誘導体 |
| CN107074823B (zh) | 2014-09-05 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
| CN107406429B (zh) | 2015-01-09 | 2021-07-06 | 基因泰克公司 | 哒嗪酮衍生物及其在治疗癌症中的用途 |
| WO2019005980A1 (en) * | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| CN115838364A (zh) * | 2022-12-20 | 2023-03-24 | 河南沁朋科技有限公司 | 一种3,3-双噻吩的合成方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69807741T2 (de) * | 1997-12-05 | 2004-07-15 | Astrazeneca Uk Ltd. | Neuartige verbindungen |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| SE0300120D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| WO2005012485A2 (en) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| EP1755611A1 (en) | 2004-06-07 | 2007-02-28 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| AU2005282721A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| US20070093515A1 (en) | 2005-08-16 | 2007-04-26 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| WO2007082546A1 (en) | 2006-01-20 | 2007-07-26 | H. Lundbeck A/S | Use of tofisopam as a pde10a inhibitor |
| WO2007085954A2 (en) | 2006-01-27 | 2007-08-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
| JP2009527562A (ja) | 2006-02-21 | 2009-07-30 | アムゲン インコーポレイティッド | ホスホジエステラーゼ１０阻害剤としてのシンノリン誘導体 |
| WO2007098169A1 (en) | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| US20090023756A1 (en) | 2006-02-23 | 2009-01-22 | Pfizer Inc | Substituted quinazolines as pde10 inhibitors |
| EP1991531A1 (en) | 2006-02-28 | 2008-11-19 | Amgen Inc. | Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors |
| US20070265258A1 (en) | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
| EP1996574A1 (en) | 2006-03-08 | 2008-12-03 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| JP2009541481A (ja) | 2006-06-26 | 2009-11-26 | ファイザー・プロダクツ・インク | Ｐｄｅ１０阻害剤としての三環式ヘテロアリール化合物 |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| CN101495476A (zh) | 2006-07-10 | 2009-07-29 | H.隆德贝克有限公司 | 6,7-二烷氧基喹唑啉、6,7-二烷氧基酞嗪和6,7-二烷氧基异喹啉的(3-芳基-哌嗪-1-基)、(2-芳基-吗啉-4-基)和(2-芳基-硫代吗啉-4-基)衍生物 |
| WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| WO2009025823A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| US20090062291A1 (en) | 2007-08-22 | 2009-03-05 | Essa Hu | Phosphodiesterase 10 inhibitors |
| WO2009029214A1 (en) | 2007-08-23 | 2009-03-05 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
| TW200918519A (en) | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
| US20090143392A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of Treating Obesity and Metabolic Disorders |
| US20090143361A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| US20090143391A1 (en) | 2007-11-30 | 2009-06-04 | Norbert Hofgen | Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10 |
| WO2009070584A1 (en) | 2007-11-30 | 2009-06-04 | Wyeth | Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10 |
| US8389567B2 (en) * | 2007-12-12 | 2013-03-05 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US8927718B2 (en) * | 2009-08-26 | 2015-01-06 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
| WO2012058133A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | Isoindolinone pde10 inhibitors |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
-
2014
- 2014-02-25 US US14/189,961 patent/US9200005B2/en not_active Expired - Fee Related
- 2014-03-12 TW TW103108560A patent/TW201441230A/zh unknown
- 2014-03-12 AU AU2014230825A patent/AU2014230825A1/en not_active Abandoned
- 2014-03-12 RU RU2015143536A patent/RU2015143536A/ru unknown
- 2014-03-12 JP JP2015562117A patent/JP2016510786A/ja active Pending
- 2014-03-12 UY UY0001035393A patent/UY35393A/es not_active Application Discontinuation
- 2014-03-12 SG SG11201507380PA patent/SG11201507380PA/en unknown
- 2014-03-12 BR BR112015022094A patent/BR112015022094A2/pt not_active IP Right Cessation
- 2014-03-12 MX MX2015012389A patent/MX2015012389A/es unknown
- 2014-03-12 WO PCT/EP2014/054810 patent/WO2014140086A1/en active Application Filing
- 2014-03-12 PE PE2015001893A patent/PE20160040A1/es not_active Application Discontinuation
- 2014-03-12 AR ARP140100879A patent/AR095267A1/es unknown
- 2014-03-12 KR KR1020157029132A patent/KR20150127724A/ko not_active Application Discontinuation
- 2014-03-12 CN CN201480014146.XA patent/CN105358561A/zh active Pending
- 2014-03-12 CA CA2902654A patent/CA2902654A1/en not_active Abandoned
- 2014-03-12 EP EP14709320.7A patent/EP2970328B1/en not_active Not-in-force
-
2015
- 2015-08-16 IL IL240593A patent/IL240593A0/en unknown
- 2015-09-03 DO DO2015000214A patent/DOP2015000214A/es unknown
- 2015-09-04 PH PH12015501962A patent/PH12015501962A1/en unknown
- 2015-09-09 CL CL2015002545A patent/CL2015002545A1/es unknown
- 2015-09-16 CR CR20150496A patent/CR20150496A/es unknown
-
2016
- 2016-06-22 HK HK16107260.0A patent/HK1219273A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201441230A (zh) | 2014-11-01 |
| AR095267A1 (es) | 2015-09-30 |
| PE20160040A1 (es) | 2016-02-11 |
| RU2015143536A (ru) | 2017-04-18 |
| MX2015012389A (es) | 2016-03-03 |
| WO2014140086A1 (en) | 2014-09-18 |
| PH12015501962A1 (en) | 2016-01-11 |
| CN105358561A (zh) | 2016-02-24 |
| JP2016510786A (ja) | 2016-04-11 |
| US20140275069A1 (en) | 2014-09-18 |
| US9200005B2 (en) | 2015-12-01 |
| DOP2015000214A (es) | 2015-12-31 |
| CL2015002545A1 (es) | 2016-07-22 |
| AU2014230825A1 (en) | 2015-09-03 |
| CR20150496A (es) | 2016-02-19 |
| EP2970328A1 (en) | 2016-01-20 |
| UY35393A (es) | 2014-10-31 |
| IL240593A0 (en) | 2015-09-24 |
| CA2902654A1 (en) | 2014-09-18 |
| BR112015022094A2 (pt) | 2018-06-12 |
| EP2970328B1 (en) | 2017-04-26 |
| KR20150127724A (ko) | 2015-11-17 |
| SG11201507380PA (en) | 2015-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279682A (en) | Benzoquinolone compounds as VMAT2 inhibitors | |
| HK1222390A1 (zh) | 抑制劑的多晶型 | |
| HK1222387A1 (zh) | 作為 抑制劑的芳基吡咯並吡啶衍生的化合物 | |
| EP2948450A4 (en) | METALLOENZYMINHIBITORVERBINDUNGEN | |
| HK1216531A1 (zh) | 新的抑制劑 | |
| HK1219273A1 (zh) | 磷酸二酯酶 型的新型抑制劑化合物 | |
| GB201317609D0 (en) | Inhibitor compounds | |
| HK1222339A1 (zh) | 金屬-β-內酰胺酶的抑制劑 | |
| EP3020718A4 (en) | NOVEL PDE4 INHIBITOR | |
| HK1221645A1 (zh) | 的苯並喹啉抑制劑 | |
| EP2968204A4 (en) | TREATMENT WITH A PHOSPHODIESTERASE HEMMER | |
| IL240763B (en) | The halopyrazoles as thrombin inhibitors | |
| HK1206728A1 (zh) | 型磷酸二酯酶之新型抑制劑化合物 | |
| ZA201507100B (en) | Synthesis of bace1 inhibitors | |
| HK1211581A1 (zh) | 新的磷酸二酯酶 型的抑制劑化合物 | |
| HK1222386A1 (zh) | 作爲詹納斯激酶的抑制劑的 -氰基甲基酰胺 | |
| EP2959896A4 (en) | INHIBITOR OF PHOSPHORYLATION OF PROTEIN T | |
| HK1211284A1 (zh) | 磷酸二酯酶 型的抑制劑化合物 | |
| GB201321328D0 (en) | Inhibitor compounds | |
| GB201323021D0 (en) | Use of kinase inhibitors | |
| GB201321227D0 (en) | Use of kinase inhibitors |